Research for effects of corroboration with apex sparing left ventricular repair surgery and hepatic growth factor using delivery sheet
利用产单证实保心尖左心室修复手术与肝生长因子的效果研究
基本信息
- 批准号:15390410
- 负责人:
- 金额:$ 6.78万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:2003
- 资助国家:日本
- 起止时间:2003 至 2005
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Background : We reported that the postoperative effects of left ventricular repair surgery (LVRS) and the initial effects were not long lasting. Hepatic growth factor was well known that facilitate an angiogenesis and has suppression of fibrosis. We estimated the effect of combine treatment both method.(1)Clinical estimation : From April 2003 to march 2005, Thirty-nine patients were performed LVRS. Left ventricular dimension (LVDd) significantly decreased and EF significantly improved after LVRS. Left ventricular (LV) apex was played important role to keep LV function. These patients were divided into 2 groups. One group was LV apex sparing group (AS Group) and other one was LV apex maneuvering group (AM Group). LV end diastolic dimension in AS Group was smaller than in AM Group. Fractional area change (FAC) in SP Group was larger than in AM Group. LV shape in AS Group was more elliptical than in AM Group.(2) Experimental study for HGF : This study was used rat model that was made heart failure with myosin antibody. These rats were divided into 2 groups with HGF delivery Group (HGF Group) and Sham Group after LVR. In HGF delivery Group, LVDd was significantly decreased, and EF and FAC were significantly improved by LVR. The fibrosis area in HGF Group was smaller than in Sham Group. Both of the concentration of Aldosterone and the expression of Bax/Bcl-2 significant suppressed in HGF Group.Conclusion : LV apex sparing LVR improved LV function. HGF delivery suppressed a fibrosis and an apoptosis on cardiac muscle. The combined treatment with LVR and HGF may be more effective for chronic heart failure patients.
背景:我们报道左心室修复手术(LVRS)的术后效果和初始效果并不持久。众所周知,肝生长因子可促进血管生成并抑制纤维化。我们对两种方法联合治疗的效果进行了评估。(1)临床评估:2003年4月至2005年3月,对39例患者进行了LVRS治疗。 LVRS 后左心室尺寸 (LVDd) 显着减小,EF 显着改善。左心室(LV)心尖部对于维持左心室功能发挥着重要作用。这些患者被分为两组。一组为左心室心尖保留组(AS 组),另一组为左心室心尖操作组(AM 组)。 AS组的左室舒张末期尺寸小于AM组。 SP组的面积变化分数(FAC)大于AM组。 AS组左心室形状较AM组更椭圆。 (2)HGF实验研究:本研究采用肌球蛋白抗体制作心力衰竭大鼠模型。 LVR后将这些大鼠分为2组:HGF递送组(HGF组)和Sham组。在HGF递送组中,LVD显着降低,并且EF和FAC通过LVR显着改善。 HGF组纤维化面积小于Sham组。 HGF组醛固酮浓度和Bax/Bcl-2表达均显着受到抑制。结论:保留左心室尖部LVR改善了左室功能。 HGF 递送抑制了心肌的纤维化和细胞凋亡。 LVR和HGF联合治疗对于慢性心力衰竭患者可能更有效。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NISHINA Takeshi其他文献
NISHINA Takeshi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NISHINA Takeshi', 18)}}的其他基金
Molecular Biological Approach to Estimate the Effect of Left Ventricular Repair for Chronic Heart Failure
评估左心室修复对慢性心力衰竭效果的分子生物学方法
- 批准号:
12671306 - 财政年份:2000
- 资助金额:
$ 6.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Decoding Dilated Cardiomyopathy in vitro: Linking Genetic Mutations to Phenotypic Dysfunction
体外解码扩张型心肌病:将基因突变与表型功能障碍联系起来
- 批准号:
495567 - 财政年份:2023
- 资助金额:
$ 6.78万 - 项目类别:
Miscellaneous Programs
Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families (DCM Next)
促进扩张型心肌病患者和家庭的诊断、患者分层和治疗取得进展 (DCM Next)
- 批准号:
10085929 - 财政年份:2023
- 资助金额:
$ 6.78万 - 项目类别:
EU-Funded
Evaluating sex specific differences in dilated cardiomyopathy
评估扩张型心肌病的性别特异性差异
- 批准号:
MR/W023830/1 - 财政年份:2023
- 资助金额:
$ 6.78万 - 项目类别:
Fellowship
Using miRNA to identify new therapeutic pathways for dilated cardiomyopathy
使用 miRNA 确定扩张型心肌病的新治疗途径
- 批准号:
10740082 - 财政年份:2023
- 资助金额:
$ 6.78万 - 项目类别:
Dysregulated mechanosignaling in dilated cardiomyopathy caused by defective Filamin C
Filamin C 缺陷引起的扩张型心肌病的机械信号失调
- 批准号:
10877387 - 财政年份:2023
- 资助金额:
$ 6.78万 - 项目类别:
Development of strategies to enhance titin (TTN) expression and treat dilated cardiomyopathy caused by TTN haploinsufficiency
开发增强肌联蛋白 (TTN) 表达并治疗 TTN 单倍体不足引起的扩张型心肌病的策略
- 批准号:
10662742 - 财政年份:2023
- 资助金额:
$ 6.78万 - 项目类别:
Elucidation of pathogenesis mechanisms and exploration of therapeutic strategies using mouse models of dilated cardiomyopathy
扩张型心肌病小鼠模型阐明发病机制并探索治疗策略
- 批准号:
23K18221 - 财政年份:2023
- 资助金额:
$ 6.78万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Discovery and Characterization of Rare Variant Effects in Dilated Cardiomyopathy via Large-Scale Biobank Analysis
通过大规模生物库分析发现和表征扩张型心肌病的罕见变异效应
- 批准号:
10682290 - 财政年份:2023
- 资助金额:
$ 6.78万 - 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 6.78万 - 项目类别:
Elucidation of Molecular Basis for Myocardial Fibrosis in Dilated Cardiomyopathy
扩张型心肌病心肌纤维化的分子基础阐明
- 批准号:
23K15174 - 财政年份:2023
- 资助金额:
$ 6.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




